TR200101751T2 - Poliol-IFN-beta konjugatları - Google Patents

Poliol-IFN-beta konjugatları

Info

Publication number
TR200101751T2
TR200101751T2 TR2001/01751T TR200101751T TR200101751T2 TR 200101751 T2 TR200101751 T2 TR 200101751T2 TR 2001/01751 T TR2001/01751 T TR 2001/01751T TR 200101751 T TR200101751 T TR 200101751T TR 200101751 T2 TR200101751 T2 TR 200101751T2
Authority
TR
Turkey
Prior art keywords
ifn
beta
polyol
peg
beta conjugates
Prior art date
Application number
TR2001/01751T
Other languages
English (en)
Inventor
El Tayar Nabil
J. Roberts Michael
Harris Milton
Sawlivich Wayne
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of TR200101751T2 publication Critical patent/TR200101751T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PEG ünitesi, insan IFN-beta Cys17 ile kovalent bag yapan PEG-IFN-beta konjugatlari bir tiolreaktif PEGilasyon ajani kullanimi ile site spesifik PEGilasyon prosesi üzerinden üretilir. Enfeksiyon, tümör ve otoimün ve enflamatör hastaliklarin tedavi edilmesine yönelik bir farmasotik kompozisyon ve bir metot da temin edilir Bu bulus, PEG ünitelerinin bir polipeptide ve daha özel anlamda IFN-beta'ya seri sekilde, adim adim eklenmesi metodu ile de ilgilidir.
TR2001/01751T 1998-04-28 1999-04-28 Poliol-IFN-beta konjugatları TR200101751T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28

Publications (1)

Publication Number Publication Date
TR200101751T2 true TR200101751T2 (tr) 2002-05-21

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/01751T TR200101751T2 (tr) 1998-04-28 1999-04-28 Poliol-IFN-beta konjugatları
TR2000/03161T TR200003161T2 (tr) 1998-04-28 1999-04-28 Poliol-IFN-Beta konjugatları

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2000/03161T TR200003161T2 (tr) 1998-04-28 1999-04-28 Poliol-IFN-Beta konjugatları

Country Status (30)

Country Link
US (3) US6638500B1 (tr)
EP (2) EP1075281B1 (tr)
JP (2) JP4574007B2 (tr)
KR (1) KR100622796B1 (tr)
CN (2) CN1187094C (tr)
AR (1) AR020070A1 (tr)
AT (2) ATE275422T1 (tr)
AU (1) AU762621B2 (tr)
BG (2) BG65046B1 (tr)
BR (1) BR9910023A (tr)
CA (2) CA2330451A1 (tr)
CY (1) CY1108022T1 (tr)
CZ (2) CZ298597B6 (tr)
DE (2) DE69936409T2 (tr)
DK (2) DK1075281T3 (tr)
EA (2) EA003789B1 (tr)
EE (1) EE05214B1 (tr)
ES (2) ES2285286T3 (tr)
HU (1) HUP0300548A3 (tr)
IL (1) IL139286A (tr)
NO (2) NO329749B1 (tr)
NZ (1) NZ507456A (tr)
PL (2) PL193352B1 (tr)
PT (2) PT1421956E (tr)
SI (2) SI1421956T1 (tr)
SK (2) SK286654B6 (tr)
TR (2) TR200101751T2 (tr)
TW (2) TWI232882B (tr)
UA (2) UA66857C2 (tr)
WO (1) WO1999055377A2 (tr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
HU229888B1 (en) * 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
CN100512879C (zh) * 1999-04-23 2009-07-15 阿尔萨公司 用于脂质体中的有可裂解键的缀合物
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
TR200101086A3 (tr) * 1999-10-15 2001-08-21
AU2223401A (en) 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Branched polyalkylene glycols
SK11672002A3 (sk) 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
DE60236796D1 (de) 2001-01-30 2010-08-05 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
DK1476181T3 (en) 2002-01-18 2016-05-23 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050502A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
ZA200609412B (en) 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
BRPI0510527A (pt) 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
EP1750751B1 (en) 2004-06-01 2013-04-10 Ares Trading S.A. Stabilized interferon liquid formulations
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
DE602005025805D1 (de) 2004-12-21 2011-02-17 Nektar Therapeutics San Carlos Stabilisierte polymer-thiol-reagenzien
WO2006071840A2 (en) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP2284191A3 (en) 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
WO2007019331A2 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Al, Corporation Conjugates of a g-csf moiety and a polymer
SG155183A1 (en) 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
WO2007025991A2 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
WO2007130453A2 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
EP2076533B1 (en) 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
ES2387236T3 (es) 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
WO2011101242A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
US20130183280A1 (en) 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
AU2011303916A1 (en) 2010-09-15 2013-03-21 Novo Nordisk A/S Factor VIII variants having a decreased cellular uptake
US9913880B2 (en) 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
KR101979045B1 (ko) * 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US20150030564A1 (en) 2012-02-29 2015-01-29 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
EP3782652A1 (en) 2014-08-19 2021-02-24 Biogen MA Inc. Pegylation method
KR20170141692A (ko) 2015-05-01 2017-12-26 알리스타 파마슈티컬즈, 인크. 안구 장애를 치료하기 위한 아디포넥틴 펩티드모방체
CN107949575B (zh) * 2015-06-19 2022-03-08 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN115920016A (zh) 2015-11-09 2023-04-07 科罗拉多州立大学董事会法人团体 用于治疗高胱氨酸尿症的组合物和方法
AU2018254410B2 (en) * 2017-04-17 2025-02-06 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
CN111356460A (zh) 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
CN113382775A (zh) 2019-01-28 2021-09-10 东丽株式会社 肝细胞生长因子或其活性片段的聚乙二醇修饰物
WO2020158691A1 (ja) 2019-01-28 2020-08-06 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
WO1995031479A1 (en) * 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
UA66857C2 (uk) 2004-06-15
ATE275422T1 (de) 2004-09-15
ES2224649T3 (es) 2005-03-01
JP2010184929A (ja) 2010-08-26
EP1421956B1 (en) 2007-06-27
NO20100324L (no) 2000-12-28
US7700314B2 (en) 2010-04-20
NO332224B1 (no) 2012-07-30
CZ20003995A3 (en) 2001-06-13
JP2002512983A (ja) 2002-05-08
HK1038194A1 (en) 2002-03-08
US20070141620A1 (en) 2007-06-21
CN1302209A (zh) 2001-07-04
DK1421956T3 (da) 2007-10-01
TWI232882B (en) 2005-05-21
UA79430C2 (en) 2007-06-25
PL193352B1 (pl) 2007-02-28
ES2285286T3 (es) 2007-11-16
WO1999055377A9 (en) 2000-03-02
EA200300382A1 (ru) 2005-02-24
DE69936409D1 (de) 2007-08-09
DE69920002T2 (de) 2005-09-22
WO1999055377A3 (en) 1999-12-29
CZ298579B6 (cs) 2007-11-14
EP1075281A2 (en) 2001-02-14
CN1187094C (zh) 2005-02-02
SK16222000A3 (sk) 2001-04-09
IL139286A (en) 2005-12-18
SK286217B6 (sk) 2008-05-06
EP1421956A1 (en) 2004-05-26
AR020070A1 (es) 2002-04-10
BG64694B1 (bg) 2005-12-30
IL139286A0 (en) 2001-11-25
CN100335503C (zh) 2007-09-05
TR200003161T2 (tr) 2001-01-22
HUP0300548A3 (en) 2005-07-28
SK286654B6 (sk) 2009-03-05
EA003789B1 (ru) 2003-10-30
BR9910023A (pt) 2000-12-26
JP4574007B2 (ja) 2010-11-04
US6638500B1 (en) 2003-10-28
DE69920002D1 (de) 2004-10-14
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
CY1108022T1 (el) 2013-09-04
HUP0300548A2 (hu) 2003-06-28
DE69936409T2 (de) 2008-04-17
BG104871A (en) 2001-07-31
EE200000614A (et) 2002-04-15
TWI266800B (en) 2006-11-21
PT1075281E (pt) 2004-11-30
SI1421956T1 (sl) 2007-10-31
CA2565375A1 (en) 1999-11-04
HK1076115A1 (en) 2006-01-06
SI1075281T1 (en) 2005-02-28
PL344490A1 (en) 2001-11-05
AU762621B2 (en) 2003-07-03
CZ298597B6 (cs) 2007-11-21
EA200001111A1 (ru) 2001-04-23
NO329749B1 (no) 2010-12-13
AU3767499A (en) 1999-11-16
WO1999055377A2 (en) 1999-11-04
DK1075281T3 (da) 2005-01-03
ATE365563T1 (de) 2007-07-15
KR100622796B1 (ko) 2006-09-13
KR20010071158A (ko) 2001-07-28
BG109291A (en) 2006-04-28
PL196533B1 (pl) 2008-01-31
BG65046B1 (bg) 2007-01-31
PT1421956E (pt) 2007-07-13
NZ507456A (en) 2003-10-31
NO20005337L (no) 2000-12-28
EA005495B1 (ru) 2005-02-24
CA2330451A1 (en) 1999-11-04
CN1637020A (zh) 2005-07-13
US7357925B2 (en) 2008-04-15
US20040043002A1 (en) 2004-03-04
NO20005337D0 (no) 2000-10-23

Similar Documents

Publication Publication Date Title
TR200101751T2 (tr) Poliol-IFN-beta konjugatları
CA2312004A1 (en) Site-specific preparation of polyethylene glycol-grf conjugates
BR9915542A (pt) Conjugados de polìmero de interferon beta-1a e usos
ATE246517T1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
ATE332918T1 (de) Neoglycoproteine
DK1028753T3 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
TWI266637B (en) Erythropoietin derivatives
MXPA02004671A (es) Conjugados de interferon gamma.
RU97108698A (ru) Конъюгаты интерферона
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
FR13C0021I2 (fr) Conjugates d'exendin-4 et leur utilisation medicale
PA8497801A1 (es) Conjugados de eritropoyetina
NO20023315D0 (no) G-CSF konjugater
TR200000015T2 (tr) Bileşikler ve metodlar
AR008378A1 (es) Conjudados de interferon
ATE356638T1 (de) Hydrolytisch abbaubare carbamatderivate von polyethylenglykol
ATE463260T1 (de) Ortspezifische duale pegylation von proteine
TR200101867T2 (tr) CCR5 modülatörleri olarak piperidinler
CY1106886T1 (el) Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων
ATE549036T1 (de) Thymosin-alpha-1-peptid/polymer-konjugate
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
ATE331730T1 (de) Neue depsipeptid-verbindung
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
TWI266801B (en) Polyol-IFN-beta conjugates